anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Crohn's disease (CD), characterized by discontinuous intestinal injury and inflammation, has been associated with changes in the luminal microbiota and impaired barrier function. Previously, the investigators have shown that in patients with CD, the mucosa-associated microbiota is altered. Additionally, it has been shown that in patients with active CD, areas of intestinal injury are associated with impaired barrier function, but the mechanisms remain unclear. Increased host proteolytic activity has been reported in both CD and ulcerative colitis (UC). The microbiota is an important source of proteases with potential inflammatory and barrier disrupting capacity. Indeed, preliminary data indicate that in UC patients the gut microbiota contributes to proteolytic imbalance. It is unknown whether this is also the case in CD. Specifically, this study postulates that the altered microbiota associated with areas of mucosal inflammation in CD, is characterized by an increased proteolytic profile. This is clinically important as it may be possible to modulate the proteolytic activity of the CD-associated bacteria by using other bacteria that produce protease inhibitors such as serpins.

In this prospective observational study, patients booked for routine white light colonoscopy under the care of the Division of Gastroenterology, Hamilton Health Sciences at the McMaster University Medical Centre and Juravinski Hospital Endoscopy Units will be invited to participate. Patients previously diagnosed with Crohn's disease who have a clinical indication for undergoing a standard white light colonoscopy, as determined by the gastroenterologist, will be invited to participate; biopsy samples and mucosal brushings will be taken from inflamed and non-inflamed areas in the ileum or colon.
PROBLEM TO BE SOLVED: To obtain a photocleavable metal-chelating agent consisting of a compound blocked by a photocleavable group and having the ability to chelate a transition metal, having the action of chelating a metal only on exposure to ultraviolet radiation, reduced in side effects, and useful for protecting the skin and hair and preventing skin aging, etc. SOLUTION: This chelating agent consists of a compound bearing a group (e.g. hydroxypyridinone, dicarboxyamine, o-hydroxybenzylamine, hydroxamate) containing a functional group (e.g. amino, CO, CN, OH) blocked by a photocleavable substituent (e.g. p-methoxyphenacyl, o-nitrobenzyl) and having the ability to chelate a transition metal (e.g. iron, copper) [for example, nitrilotriacetic p-methoxyphenacyl triester].
Regenerating gene family member 4 (Reg4) has been implicated in acute pancreatitis, but its precise functions and involved mechanisms have remained unclear. Herein, we sought to investigate the contribution of Reg4 to the pathogenesis of pancreatitis and evaluate its therapeutic effects in experimental pancreatitis. In acute pancreatitis, Reg4 deletion increases inflammatory infiltrates and mitochondrial cell death and decreases autophagy recovery, which are rescued by the administration of recombinant Reg4 (rReg4) protein. In chronic pancreatitis, Reg4 deficiency aggravates inflammation and fibrosis and inhibits compensatory cell proliferation. Moreover, C-X-C motif ligand 12 (CXCL12)/C-X-C motif receptor 4 (CXCR4) axis is sustained and activated in Reg4-deficient pancreas. The detrimental effects of Reg4 deletion are attenuated by the administration of the approved CXCR4 antagonist plerixafor (AMD3100). Mechanistically, Reg4 mediates its function in pancreatitis potentially via binding its receptor exostosin-like glycosyltransferase 3 (Extl3). In conclusion, our findings suggest that Reg4 exerts a therapeutic effect during pancreatitis by limiting inflammation and fibrosis and improving cellular regeneration.
A method is provided for synthesizing beads using starting ceramic, metal, or mineral powders. Typical size of these round beads can range from about 0.1 mm to about 10 mm based on the processing variables. In the method, a slip is obtained which contains a metal, ceramic, and/or mineral powder dispersed in a solvent and an organic binder, such as a grain flour. Droplets of the slip are contacted with heated oil for a sufficient time to form beads. The beads are separated from the oil and dried to remove entrained water. The beads are fired at a temperature sufficient to produce beads possessing desired physical or chemical characteristics. The beads have useful biomedical applications as bone filler materials for bone fixation and bone growth. The beads may be coated with chemical catalyst agents and function as catalyst supports in chemical processes.
The invention relates to a preparation used for preventing and treating diabetes mellitus and heart cerebrovascular disease. Propolis, pearl powder, ginkgo biloba extract, bitter melon extract and chromium picolinate are used as raw materials. The mass proportion is as follows: 1000-1400 parts of propolis, 80-1400 parts of pearl powder, 400-800 parts of ginkgo biloba extract, 800-1200 parts of bitter melon extract, 1-4 parts of chromium picolinate and a proper amount of pharmaceutic adjuvant (such as dextrin, magnesium stearate and the like). The raw materials are made into capsules, granules, tablets and the like by the process flow of crushing, mixing, pelletizing and the like. The effects are as follows: the whole are rich in a plurality of active substances such as bitter melon saponins, flavone, organic chromium; and by improving nutrition, adjusting metabolism, promoting pancreas repair and increasing glucose tolerance factors, the functions of reducing blood sugar, adjusting blood fat and preventing and treating heart cerebrovascular disease are brought into play. As proved by human trial and animal test, the preparation is applicable to dizziness, dispiritedness and lassitude, insomnia and amnesia, limb numbness, chest distress, palpitation and other symptoms, and has fine values of clinical application.
Provided herein are antibodies, such as fully human antibodies, that immunospecifically bind to an hLIGHT polypeptide. Also provided are isolated nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Further provided are vectors and host cells comprising nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Also provided are methods of making antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Also provided herein is a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject an antibody, such as a fully human antibody, that immunospecifically binds to a hLIGHT polypeptide.; In preferred embodiments, that anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
1\. Use aseptic technique to clean ampule. Gently tap the top of the ampule to assist the flow of the solution from the upper portion of the ampule to the lower portion.   
2\. Locate the blue dot on the upper portion of the ampule. Below this dot is a small score on the neck of the ampule. Hold the ampule with the blue dot  facing away from you.   
3\. Cover the vial with an appropriate wipe. Apply pressure to the top and bottom portions of the ampule to snap the ampule open away from you.
Rationale: Renal fibrosis, with no therapeutic approaches, is a common pathological feature in various chronic kidney diseases (CKD). Tubular cell injury plays a pivotal role in renal fibrosis. Commonly, injured tubular cells exhibit significant lipid accumulation. However, the underlying mechanisms remain poorly understood. Methods: 2-arachidonoylglycerol (2-AG) levels in CKD patients and CKD model specimens were measured using mass spectrometry. 2-AG-loaded nanoparticles were infused into unilateral ureteral obstruction (UUO) mice. Lipid accumulation and renal fibrosis were tested. Furthermore, monoacylglycerol lipase (MAGL), the hydrolyzing enzyme of 2-AG, was assessed in CKD patients and models. Tubular cell-specific MAGL knock-in mice were generated. Moreover, MAGL recombination protein was also administered to unilateral ischemia reperfusion injury (UIRI) mice. Besides, a series of methods including RNA sequencing, metabolomics, primary cell culture, lipid staining, etc. were used. Results: 2-AG was increased in the serum or kidneys from CKD patients and models. Supplement of 2-AG further induced lipid accumulation and fibrogenesis through cannabinoid receptor type 2 (CB2)/β-catenin signaling. β-catenin knockout blocked 2-AG/CB2-induced fatty acid β-oxidation (FAO) deficiency and lipid accumulation. Remarkably, MAGL significantly decreased in CKD, aligning with lipid accumulation and fibrosis. Specific transgene of MAGL in tubular cells significantly preserved FAO, inhibited lipid-mediated toxicity in tubular cells, and finally retarded fibrogenesis. Additionally, supplementation of MAGL in UIRI mice also preserved FAO function, inhibited lipid accumulation, and protected against renal fibrosis. Conclusion: MAGL is a potential diagnostic marker for kidney function decline, and also serves as a new therapeutic target for renal fibrosis through ameliorating lipotoxicity.
Methods for identifying a ligand of a G protein-coupled receptor (GPCR), such as ligands of orphan GPCRs, are provided. The methods include providing at least one cell containing a G-alpha protein that couples to at least one GPCR. The at least one cell is transformed with a recombinant DNA including a nucleic acid encoding a GPCR and the nucleic acid is expressed. At least one chemical compound is contacted with the transformed at least one cell and a calcium sensitive-fluorescent dye to form a first mixture. The at least one chemical compound is also contacted with at least one untransformed cell and the calcium sensitive-fluorescent dye to form a second mixture. Fluorescence from the first and second mixtures is measured and compared to determine whether the at least one chemical compound is a ligand of the GPCR. Nucleotide sequences, amino acid sequences, vectors, cells, and pharmaceuticals thereof are provided.
The invention relates to a pharmaceutical composition of a blood platelet ADP receptor antagonist and B vitamins. The pharmaceutical composition is formed by the treatment effective dose of the blood platelet ADP receptor antagonist and one of the medical precursor, active metabolites and salt of the blood platelet ADP receptor antagonist, one or more of B-vitamins of the treatment effective dose, and carriers which are acceptable in pharmacy, wherein the blood platelet ADP receptor antagonist comprises ticlopidine, clopidogrel, prasugrel, ticagrelor, elinogrel and the like. The B-vitamins comprise vitamin B6, vitamin B12, folic acid compounds and optimized folic acid compounds. The invention further relates to application of the pharmaceutical composition in preparing drugs for preventing thromboembolic diseases. Drugs made of the pharmaceutical composition have the more remarkable effect of preventing or delaying the thromboembolic diseases on the basis of effectively inhibiting blood platelet functions. In addition, patients can take medicine conveniently, and compliance is improved.
The aim of this study is to determine the impact of the COVID-19 pandemic on the Dutch surgical care, expressed as number of performed procedures, altered treatment plans, and surgical outcomes in the Netherlands during the year 2020. This was done by executing a nationwide prospective cohort study, under the name "Dutch COVIDsurg II Snapshot Study". This study was conducted in collaboration with the Dutch Institute of Clinical Auditing (DICA). For this study, the surgical audits for lung cancer surgery (DLCA-S), Upper gastrointestinal cancer surgery (DUCA), pancreatic cancer surgery (DPCA), hepatobiliary surgery (DHBA), colorectal cancer surgery (DCRA), hip fracture surgery (DHFA), aortic aneurysm surgery (DSAA), and bariatric surgery (DATO), were expanded with an additional COVID-19 survey, since August 2020. This survey focused on alterations in, or delay of treatment and diagnostics, perioperative outcomes, and specific COVID-19 related symptoms and complications during the COVID-19 pandemic. All academic-, general community-, teaching- and non-teaching hospitals in the Netherlands performing pulmonary, upper gastrointestinal, pancreatic, hepatobiliary, colorectal, hip fracture, aneurysmal or bariatric procedures were approached to participate in the Dutch COVIDSurg II Snapshot study. Patients who underwent surgery during the period January 1st 2018 until December 31st 2019, were included in the historical cohort. Patients who underwent a surgical procedure in the period January 1st 2020 until December 31st 2020 were included in the study group.
Receive (1) standard care advice based on general health benefits of healthy lifestyle habits (benefits of adherence to national guidelines about physical activity and dietary habits as well as limiting alcohol intake and smoking withdrawal), (2) feedback about current lifestyle habits and health status. Tobacco users and subjects with high alcohol consumption will be referred to specialized care.
Participants received matching placebo once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.
The invention discloses a technology for preparing compound hydrolat by taking rose-scented grape vine leaves as a main raw material and rose (or edible Chinese rose) and russianolive flower as auxiliary materials. The muscat grape has rose fragrance, and its vine leaves are edible. Besides being used as food materials, the muscat grape vine leaves are also an important Chinese medicinal material in ancient traditional Chinese medicine, have a good hemostatic effect, and can also play roles in dispelling wind, removing dampness, detoxifying and reducing swelling. The invention relates to a rose grape vine leaf hydrolat which is a compound hydrolat prepared by using fresh rose grape vine leaves trimmed from 7-8 months as a main raw material and adopting a distillation extraction method. Has the health care and health preserving effects of benefiting liver and kidney, relieving emotion, moistening lung and beautifying, and the like. Can be taken orally directly or used as skin care product.
CATAFLAM™ (diclofenac potassium tablets, USP) are a benzeneacetic acid derivative. CATAFLAM, is available as tablets of 50 mg (light brown) for oral administration. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monopotassium salt. The molecular weight is 334.25. Its molecular formula is C14H10Cl2NKO2, and it has the following structural formula:

Each 50 mg CATAFLAM intended for oral administration, contains 50 mg diclofenac potassium for oral administration. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxyethyl cellulose, iron oxide red, magnesium stearate, methanol, polyethylene glycol, povidone, sodium bicarbonate, titanium dioxide and yellow iron oxide.
A medical device, such as stent, for delivering a biologically active material to body tissue of a patient, and a method for making such a medical device are described. The medical device has a coating layer on its surface. The coating layer includes a metal having a plurality of pores and a biologically active material dispersed in the pores. The pores are connected to the outer surface of the coating layer. The coating layer may be formed by applying a coating composition comprising two or more metals (such as gold and silver) to the surface of the medical device and removing one of the metals to form the porous coating layer. This layer of the disclosed medical device has an increased surface area, and, thus, can be loaded with a greater amount of biologically active material than a medical device without such coating.
An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.
PURPOSE: A cultured cartilage tissue material is provided to produce a cartilage tissue which is identical with a cartilage tissue located in a body, thereby shortening a therapeutic period and facilitating the production of a large cartilage tissue material. CONSTITUTION: A cultured cartilage tissue material includes cartilage cells which are used in the restoration of cartilage. The cultured cartilage tissue material is a mixture of bioabsorbable polymers and cartilage cells with a concentration of 1×10^7 cell/cm^3 to 1×10^9 cell/cm^3. In the cultured cartilage tissue material, a thickness of a minimum portion is 2.2 mm to 100 mm, and a volume ratio of the cartilage cells and bioabsorbable polymer is 7:3 to 9.5:0.5. Glycosaminoglycan productivity is 0.001 ng to 0.2 ng per unit cell. A content ratio of I-form collagen and II type collagen is 10:90 to 1:99. 0.01 mg to 0.65 mg per 1 mg organization dry weight of the II type collagen is included.
This is a pre-experimental "one group pretest-posttest" design to improve COVID-19 associated health outcomes and willingness and uptake toward testing and vaccination among 310 Hispanic and African American public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our COVID-19 health ambassadors and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention.
The invention relates to traditional Chinese medicine salty mud for hot compress. The traditional Chinese medicine salty mud comprises traditional Chinese medicines and salty mud. The traditional Chinese medicines include, by weight, 9 parts of Flos Carthami, 12 parts of Radix Angelicae Sinensis, 9 parts of olibanum, 15 parts of Cortex Erythrinae, 9 parts of Radix Angelicae Pubescentis, 15 parts of Radix Clematidis, 9 parts of Lignum Sappan, 15 parts of Herba Lycopodii and 9 parts of myrrh, wherein a weight ratio of the traditional Chinese medicines to the salty mud is 102:1250-1500. The traditional Chinese medicine salty mud for hot compress is capable of quickly expanding local blood capillaries and relaxing muscles to enable effective components of salt to enter bodies quickly, has efficacies of muscle and bone permeating, cold dispelling, damp removing, Qi and blood circulation promoting, inflammation diminishing, heat clearing, pathogenic stasis eliminating, muscle relaxing, meridian activating, blood invigorating, stasis removing, detoxifying, swelling alleviating and tissue regeneration promoting and is capable of treating symptoms of menstrual block, rheumatic arthralgia, postnatal stasis, abdominal mass stomachache, tendon and vessel spasm and the like. The traditional Chinese medicine salty mud is heated and applied to acupoints on the human skin surface to permeate into the skin, and accordingly a medical healthcare effect is achieved. The traditional Chinese medicine salty mud is suitable for the whole body; due to addition of the salty mud, efficacies of the traditional Chinese medicine salty mud are better than combined effects of traditional Chinese medicines and salt.
AIM: Chronic wounds, defined as wounds that do not heal in a logical set of stages, impact patients' quality of life by disrupting their self-esteem, sleep, social interaction, work capacity, and psychological well-being. Chronic wounds are a prevalent problem in Oman due to the high number of patients with diabetes, sickle cell disease, road traffic accidents, and decubitus ulcer. Therefore, it is paramount to analyse the health-related quality of life (HRQOL) of these patients with chronic wounds.
MATERIAL AND METHODS: An observational, cross-sectional, descriptive study with a quantitative approach was conducted among 275 adult patients with chronic wounds in three tertiary hospitals of Muscat from June to December 2021 using a self-reported Cardiff life wound impact questionnaire and the Bates-Jensen wound assessment tool. Data were analysed with IBM SPSS version 23 using inferential statistics and chi-square test.
RESULTS: We found that the majority of participants were men (178; 64.7 %), aged between 41 and 60 years (107; 38.9 %), predominantly with diabetic wounds (80; 29.1 %). Respondents reported poor HRQOL across all domains: well-being (63.24 ± 18.092), physical (53.24 ± 18.387), and social (59.54 ± 19.025). Statistically significant poorer HRQOL was observed among the elderly above 60 years, illiterates, those with traumatic wounds, and those receiving medication and dressing as treatment.
CONCLUSIONS: Our findings indicate that Omani patients with chronic wounds experience low HRQOL. It is imperative for healthcare providers to offer comprehensive care to these patients. To enhance their quality of life and alleviate suffering, evaluating both the wounds and HRQOL is essential. Such assessments will enable the optimisation of treatment and coping strategies for patients.
There has been a rather long tradition of PE for patients with arthritis. A recent systematic review found that PE had small short-term effects on disability, joint counts, patient global assessment, psychological status and depression, but this effect disappeared on the latest time of follow up (3-14 months). A recent large British study also failed to show an effect on pain, physical functioning, or contact with primary care after 12 months, but found a significant effect on anxiety and improved the participants' perceived self efficacy. This indicates that the present forms of interventions fails to show a long term effect. One possible reason for the lack of long term effect might be that these interventions are given to groups only. Patients seem to prefer one-to-one interaction regarding information about the disease and its treatment together with emotional aspects, while education in groups are preferred for physical training and relational topics.
Patients with a germline TP53 alteration included in this study will undergo their usual surveillance with their treating team. In addition to their routine scans or examinations, they will provide blood samples at enrollment, during the study (optional) and at the end of their participation (at 12 months). The results of any radiological scan undergone during this period will be collected retrospectively and added to their data collection, which will allow for a correlative analysis between the genetic and epigenetic results and radiological outcomes.